Infusion Associates

Grand Rapids, Michigan 49525

1 studies enrolling now · 16 studies all time

What they study most

Crohn's Disease, Fabry Disease, Gout, Pompe Disease, Refractory Chronic Gout, SARS-CoV-2 Infection, Ulcerative Colitis

Studies at this site

A Multi-Country Observational Study of Safety and Effectiveness of Elfabrio® in Fabry Patients — Recruiting now
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis — Running, not enrolling
A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry Disease — Running, not enrolling
Open Label Extension of 2 mg/kg Pegunigalsidase Alfa (PRX-102) Every 4 Weeks in Adult Fabry Disease Patients — Completed
Open Label Extension Study of 1 mg/kg Pegunigalsidase Alfa Every 2 Weeks in Patients With Fabry Disease — Completed
First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221 — Completed
A Study to Compare S-217622 With Placebo in Non-Hospitalized Participants With COVID-19 — Completed
A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease — Completed
Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry Disease — Completed
Open-Label Expanded Access Treatment With Pegunigalsidase Alfa for Fabry Disease Patients — APPROVED_FOR_MARKETING
Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled Gout — Completed
Safety and Efficacy of Deucravacitinib in Participants With Moderate to Severe Ulcerative Colitis — Completed
Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function — Completed
Safety, Efficacy, & PK of PRX-102 in Patients With Fabry Disease Administered Intravenously Every 4 Weeks — Completed
Treatment Protocol of Replagal for Patients With Fabry Disease — NO_LONGER_AVAILABLE
Observational Study of the Use of Pegloticase (KRYSTEXXA®) in Refractory Chronic Gout — Completed